Anzeige
Mehr »
Login
Dienstag, 14.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
Das 13-Millionen-Unternehmen mit einer Monster-Entdeckung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0JMY1 | ISIN: CA20676U1049 | Ticker-Symbol: KD4
Tradegate
23.12.24
15:00 Uhr
0,083 Euro
-0,009
-9,57 %
Branche
Öl/Gas
Aktienmarkt
Sonstige
1-Jahres-Chart
CONDOR RESOURCES INC Chart 1 Jahr
5-Tage-Chart
CONDOR RESOURCES INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,0840,10010:44
ACCESSWIRE
354 Leser
Artikel bewerten:
(2)

Condor Resources Inc.: Condor Resources Announces Results of Annual General and Special Meeting of Shareholders

Finanznachrichten News

VANCOUVER, BC / ACCESSWIRE / December 12, 2024 / Condor Resources Inc. ("Condor" or the "Company") (TSXV:CN) is pleased to announce the voting results of the Company's 2024 Annual General and Special Shareholders' Meeting (the "Meeting") held on December 11, 2024 at 10am PST, in Vancouver, British Columbia.

A total of 32,169,685 common shares were voted at the Meeting, representing 22.79% of the votes attached to all outstanding common shares of the Company. All matters presented for shareholder approval at the Meeting were duly authorized and approved as follows:

Number of Directors to be Elected

On a vote by a show of hands, the resolution to set the number of directors to be elected at the meeting at six (6) was approved, and all Directors up for election were duly approved.

Appointment of Auditors

De Visser Gray LLP, Chartered Professional Accountants was appointed as auditor of the Company for the ensuing year and the directors of the Corporation were authorized to fix the auditor's remuneration. Details of the voting results are as follows:

Total Votes

% of Votes Cast

Votes in Favour

32,169,685

100.00%

Votes Withheld

0

0%

Total Votes Cast

32,169,685

Omnibus Equity Incentive Plan

An ordinary resolution adopting the Company's omnibus equity incentive plan, all as more particularly described in the accompanying management information circular, was approved. Details of the voting results are as follows:

Total Votes

% of Votes Cast

Votes in Favour

23,764,781

95.555%

Votes Withheld

107,174

0.455%

Total Votes Cast

23,871,955

The Company also wishes to announce that Mr. Lyle Davis did not stand for re-election to the Board of Directors of Condor Resources. Mr. Davis was a long-standing Director of the Company as well as CEO from July 2013 until April 2024. Management and the Board wish to express their sincere gratitude to Mr. Davis for all his contributions to the Company and wish him the best in future endeavors.

About Condor Resources Inc.

Condor Resources is a precious and base metals exploration company focused on its portfolio of projects in Peru. The Company's flagship project, Pucamayo, is an 85 km2 property containing a high sulfidation epithermal system with disseminated precious metals mineralization with a large lithocap alteration visible at surface. The Huiñac Punta project, a 7,200 Ha property in Huanuco, Peru, has the potential to host a large carbonate replacement style (CRD) silver-dominant polymetallic mineralized body with the potential for discovery of a bulk tonnage silver and base metals deposit. The Company has optioned several large projects to partners who continue to advance these projects. The Company's award-winning exploration team in Peru has a long history of success in discovering and advancing high quality exploration projects and managing the social aspects of its exploration activities.

For more information, please visit the Company's website at www.condorresources.com.

ON BEHALF OF THE BOARD

Chris Buncic
President & Chief Executive Officer

For further information please contact the Company at 1-866-642-5707, or by email at info@condorresources.com

Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of applicable securities law. Forward-looking statements are frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Such forward-looking statements include, but are not limited to the Company's expectations with respect to the use of proceeds and the use of the available funds following completion of the LIFE Offering and statements respecting completion of the LIFE Offering and receipt of all regulatory approvals in respect of the LIFE Offering, including approval of the TSXV.

Although the Company believes that the expectations reflected in applicable forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. Such forward-looking statements are subject to risks and uncertainties, including risks associated with the business of mineral exploration and development; continued availability of capital and financing; general political and economic conditions, fluctuations in metal prices and other market-related risks, including any volatility in the Company's share price, that may cause actual results, performance or developments to differ materially from those contained in such statements. Therefore, readers are cautioned not to place undue reliance on forward-looking statements and forward-looking information. Condor does not assume any obligation to update or revise its forward-looking statements, whether as a result of new information, future or otherwise, except as required by applicable law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

SOURCE: Condor Resources Inc.



View the original press release on accesswire.com

© 2024 ACCESSWIRE
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.